Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis

Elodie Rivière†, Jérémie Sellam†, Juliette Pascaud¹, Philippe Ravaud³, Jacques-Eric Gottenberg⁴ and Xavier Mariette¹,⁵*

Trial registration: Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis (ROC), registered 22 October 2009, NCT01000441

Keywords: Interleukin 33, Personalized medicine, Rheumatoid arthritis, Biologic agents

Interleukin (IL)-33 may play a role in rheumatoid arthritis (RA) pathophysiology as shown by human studies and murine models [1]. Previously, we demonstrated that detectable serum IL-33 predicts clinical response to rituximab independently of auto-antibody status [2].

Here, we aimed to investigate whether the prediction of therapeutic response using serum IL-33 level is generalizable to all biologic agents, including TNF inhibitors (TNFi) and non-TNFi in RA.

We set up an ancillary study of the ROC (Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for RA) trial (NCT01000441) which compared the efficacy of TNFi vs non-TNFi in patients with insufficient response to a first TNFi [3]. Three hundred patients were randomized, and treatment efficacy was evaluated at 24 weeks according to EULAR response, showing that a non-TNFi was more effective in achieving EULAR response than a TNFi.

Serum IL-33 level was assessed before treatment using an accurate enzyme-linked immunosorbent assay (ELISA IL-33, Quantikine, R&D Systems) [4]. Statistical analyses used Prism (Mann-Whitney and Fisher tests for quantitative and qualitative values, respectively). Serum IL-33 level was defined as detectable when > 6.25 pg/mL (lower threshold).

Results were analyzed for 267 patients with available serum and clinical data (Table 1). Serum IL-33 level was detectable for 109/267 (40.8%) patients (mean ± standard deviation serum level was 49.7 ± 61.0 pg/mL when detectable) (Table 2). IL-33 detection was associated with auto-antibody positivity: rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide antibody (anti-CCP), either combined or analyzed separately (Table 3). Auto-antibody positivity was not associated with response to the different treatment: TNFi (N = 132, odds ratio (OR) = 1.1, 95% confidence interval (CI) = 0.39–3.16), non-TNFi (N = 130, OR = 1.5, 95% CI = 0.40–5.62), or different sub-groups of non-TNFi (data not shown). There was no association between IL-33 detection and response to TNFi as well as to non-TNFi drugs overall or analyzed separately (Table 2). Likewise, there was no difference when comparing the levels of serum IL-33 between responders and non-responders in TNFi and non-TNFi groups (data not shown).

Thus, this new study confirms the association between serum IL-33 detection and seropositivity in RA patients. However, it did not replicate the association between IL-33 detection and response to rituximab.
Table 1 Characteristics of the patients included in the ancillary study of the ROC trial

| Characteristics          | TNFi             | Non-TNFi biologic | Total         |
|--------------------------|------------------|-------------------|---------------|
| Number of women (%)      | 114 (85.7)       | 110 (82.1)        | 224 (83.9)    |
| Mean age (SD)            | 55.9 (13.0)      | 58.4 (11.2)       | 57.2 (12.1)   |
| Number rheumatoid factor-positive (%) | 108 (82.4)     | 101 (76.5)        | 209 (79.8)    |
| Number anti-CCP-positive (%) | 102 (79.7)     | 105 (82.7)        | 207 (81.2)    |
| Mean DAS28-CRP (SD)      | 4.7 (0.9)        | 4.8 (1.1)         | 4.8 (1.0)     |

Table 2 EULAR response, IL-33 detectability rates and association between IL-33 detection and response to tumor necrosis factor inhibitor (TNFi; including adalimumab, certolizumab, etanercept and infliximab) and non-TNFi (including abatacept, rituximab, and tocilizumab) in patients from the ROC study

| Treatment          | Number of patients | Number of EULAR responders (%) | Number of detectable IL-33 among all patients (%) | Number of detectable IL-33 among EULAR responders (%) | Association between IL-33 detectability and EULAR response (OR [95% CI]) |
|--------------------|--------------------|--------------------------------|---------------------------------------------------|------------------------------------------------------|---------------------------------------------------------------------|
| TNFi               |                    |                                |                                                   |                                                      |                                                                     |
| Adalimumab         | 53                 | 30 (56.6)                      | 23 (43.4)                                         | 14 (46.7)                                            | 1.4 [0.5–4.1]                                                      |
| Etanercept         | 49                 | 29 (59.2)                      | 20 (40.8)                                         | 13 (44.8)                                            | 1.5 [0.5–5.0]                                                      |
| Certolizumab       | 23                 | 10 (43.5)                      | 10 (43.5)                                         | 5 (50.0)                                             | 1.6 [0.3–8.5]                                                      |
| Infliximab         | 8                  | 1 (12.5)                       | 3 (37.5)                                          | 1 (100)                                              | 6.6 [0.2–226]                                                     |
| Total TNFi         | 133                | 70 (52.6)                      | 56 (42.1)                                         | 33 (47.1)                                            | 1.6 [0.8–3.1]                                                      |
| Non-TNFi           |                    |                                |                                                   |                                                      |                                                                     |
| Rituximab          | 37                 | 20 (54.0)                      | 10 (27.0)                                         | 6 (30.0)                                             | 1.4 [0.3–6.1]                                                      |
| Abatacept          | 30                 | 18 (60.0)                      | 11 (36.6)                                         | 8 (44.4)                                             | 2.4 [0.5–11.9]                                                     |
| Tocilizumab        | 67                 | 53 (79.1)                      | 32 (47.8)                                         | 25 (47.2)                                            | 0.9 [0.3–2.9]                                                      |
| Total non-TNFi     | 134                | 91 (67.9)                      | 53 (39.6)                                         | 39 (42.9)                                            | 1.6 [0.7–3.3]                                                      |

Results are presented as odds ratios (OR) [95% confidence intervals (CI)]

Table 3 Association between IL-33 detection and auto-antibody positivity

| Auto-antibody status | Number of patients | OR | 95% CI |
|----------------------|--------------------|----|--------|
| RF+ and/or anti-CCP+ vs RF– and anti-CCP– | 262 | 21.1 | 2.8-158.3 |
| RF+ vs RF–           | 263 | 9.7 | 3.7-25.3 |
| Anti-CCP+ vs anti-CCP– | 255 | 2.7 | 1.3- 5.7 |

Results are presented as odds ratios (OR), 95% confidence intervals (CI) for each factor
RF rheumatoid factor, Anti-CCP anti-cyclic citrullinated peptide antibody
This may be due to a lack of power related to the number of patients who received this treatment (N = 37), but it may also reflect the difficulty of studying IL-33 as a possible predictor of response given its association with seropositivity, which is a well-known factor associated with response to some biologics such as rituximab or abatacept [5].

In conclusion, we confirm that serum IL-33 detection is associated with auto-antibody positivity but is not a predictive marker for response to TNFi and non-TNFi in RA.

Abbreviations
Anti-CCP: Anti-cyclic citrullinated peptide; CI: Confidence interval; ELISA: Enzyme-linked immunosorbent assay; EULAR: European League Against Rheumatism; Ig: Immunoglobulin; IL: Interleukin; OR: Odds ratio; RA: Rheumatoid arthritis; RF: Rheumatoid factor; TNFi: Tumor necrosis factor inhibitor

Acknowledgements
The authors thank all patients for participating in this study and all investigators who included patients in the ROC study: Olivier Brocq, MD; Aleth Perdriger, MD; Slim Lassoued, MD; Jean-Marie Berthelot, MD; Daniel Wendling, MD, PhD; Liana Euler-Ziegler, MD; Martin Soubrrier, MD; Christophe Richez, MD, PhD; Bruno Fautrel, MD, PhD; Arnaud L. Constantini, MD, PhD; Jacques Morel, MD, PhD; Melanie Gilson, MD; Gregoire Cormier, MD; Jean-Hugues Salmon, MD; Stephanie Rist, MD; Frederic Licot, MD, PhD; Hubert Marotte, MD, PhD; Christine Bonnet, MD; Christian Marcelli, MD, PhD; Olivier Meyer, MD, PhD; Elisabeth Solau-Gervais, MD, PhD; Sandrine Guis, MD, PhD; Jean-Marc Ziza, MD; Charles Zarnitsky, MD; Isabelle Chay-Valkenaere, MD, PhD; Olivier Vittecoq, MD, PhD; Alain Saraux, MD, PhD; Yves-Marie Pers, MD; Martine Gayraud, MD; Gilles Bolla, MD; Pascal Claudepierre, MD, PhD; Marc Ardizzone, MD; Emmanuelle Dennis, MD; Maxime A. Breban, MD, PhD; Olivier Fain, MD, PhD; Jean-Charles Balblanc, MD; Ouafaa Aberkane, PhD; Marion Vazel, PhD; Christelle Back, PhD; Sophie Candon, MD, PhD; Lucienne Chatenoud, MD, PhD; Elodie Perrodeau, MSc; Jean Sibilia, MD

Funding
The main ROC study was sponsored by the French Ministry of Health (Programme Hospitalier de Recherche Clinique National 2009/4507 EU4RACT No. 2009-013482-26) and promoted by The Direction de la Recherche Clinique et de l’Innovation, Strasbourg University Hospital. The funding agency had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; the decision to submit for publication or preparation, review, or approval of the manuscript for publication.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors’ contributions
ER participated in conception and design of the study, performed acquisition of the data, performed the statistical analysis and interpretation of the results, and wrote the manuscript. JS participated in conception and design of the study, participated in the statistical analysis and interpretation of the results, and wrote the manuscript. JP participated in the design of the study and the acquisition of the data. PR participated in interpretation of the data. JEG is the principal investigator of the main ROC. He participated in the conception and design of the study and in interpretation of the data. XM participated in conception and design of the study, statistical analysis and interpretation of the results, and wrote the manuscript. All authors reviewed and approved the final manuscript.

Ethics approval and consent to participate
The trial (Clinicaltrials.gov identifier NCT01000441) was approved by the institutional review board of the Comité de Protection des Personnes-Est 1, Strasbourg, France. The study was conducted according to the current regulations of the International Conference on Harmonization guidelines and the principles of the Declaration of Helsinki. All patients gave written informed consent after receiving oral and written information about the trial.

Consent for publication
We confirm that all authors approved the manuscript for submission.

Competing interests
Dr. Rivière reported receiving a PhD grant from Fondation Arthritis Courtin. Dr. Sellam reported receiving grant support from Roche, Bristol-Myers Squibb, and Pfizer and personal fees from Roche, Pfizer, Abbvie, Bristol-Myers Squibb, Merck Sharp and Dohme, UCB, Janssen, Sandoz, and Novartis. Dr. Gottenberg reported receiving grant support from Abbvie, Pfizer, and Roche and personal fees from Bristol-Myers Squibb, Merck, Sharp, and Dohme, UCB, GlaxoSmithKline, and Novartis. Dr. Mariette reported receiving personal fees from Pfizer, UCB, Bristol-Myers Squibb, and GlaxoSmithKline and grant support from Roche, Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, and Biogen. No other disclosures were reported.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Immunology of viral Infections and Autoimmune Diseases, IDMIT, CEA - Université Paris Sud - INSERM UMR1184, Le Kremlin Bicêtre & Fontenay aux Roses, France. 2Department of Rheumatology, Saint-Antoine Hospital, Université Paris 6, INSERM UMR398, DHU UB, Paris, France. 3Department of Epidemiology and Biostatistics, Hotel Dieu, Paris, France. 4Department of Rheumatology, National Reference Center for Systemic Autoimmune Diseases, Strasbourg University Hospital, Université de Strasbourg, Strasbourg, France. 5Department of Rheumatology, Université Paris Sud, 63 rue Gabriel Péri, 94270 Le Kremlin Bicêtre, France.

Published online: 08 June 2018

References
1. Sellam J, Marion-Thore S, Dumont F, Jacques S, Garchon H-J, Rouanet S, et al. Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial. Arthritis Rheumatol. 2014;66(8):2015–25.
2. Sellam J, Rivière E, Courties A, Rouzaire P-O, Tolusso B, Vital EM, et al. Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Res Ther. 2016;18(1):294.
3. Gottenberg J-E, Brocq O, Perdriger S, Lassoued S, Berthelot J-M, Wendling D, et al. Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA. 2016;316(11):1172–80.
4. Rivière E, Ly B, Boudaoud S, Chavez H, Nocturne G, Chanson P, et al. Pitfalls for detecting interleukin-33 by ELISA in the serum of patients with primary Sjögren syndrome: comparison of different kits. Ann Rheum Dis. 2016;75(3):633–5.
5. Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Loët X, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum. 2011;63(9):33–8.